{"nctId":"NCT00660907","briefTitle":"Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients","startDateStruct":{"date":"2008-03"},"conditions":["Type 2 Diabetes"],"count":1217,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: metformin hydrochloride"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: glipizide","Drug: metformin hydrochloride"]}],"interventions":[{"name":"dapagliflozin","otherNames":[]},{"name":"glipizide","otherNames":["Glucotrol"]},{"name":"metformin hydrochloride","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes\n* Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment\n* HbA1c \\>6.5% and \\</=10%\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Insulin therapy within one year of enrolment\n* Renal (kidney) failure or dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":null},{"groupId":"OG001","value":"-0.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight","description":"To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.22","spread":null},{"groupId":"OG001","value":"1.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With at Least One Episode of Hypoglycemia","description":"To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Body Weight Reduction of at Least 5%","description":"To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":406},"commonTop":["Hypoglycemia","Nasopharyngitis","Hypertension","Influenza","Upper Respiratory Tract Infection"]}}}